Hemogenyx Pharmaceuticals annual net income
2020
2021
2022
2023
2024
2025
Hemogenyx Pharmaceuticals Net Income Growth & History (HEMO)
Hemogenyx Pharmaceuticals's net income was −£9.8M for fiscal 2025.
View full Hemogenyx Pharmaceuticals company overviewHemogenyx Pharmaceuticals annual net income history
| Fiscal year | Period ended | Net income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −£9.8M | −£4.1M | — |
| 2024 | 2024-12-31 | −£5.6M | £1.1M | — |
| 2023 | 2023-12-31 | −£6.7M | −£2.7M | — |
| 2022 | 2022-12-31 | −£4.0M | £1.1M | — |
| 2021 | 2021-12-31 | −£5.1M | −£3.0M | — |
| 2020 | 2020-12-31 | −£2.1M | — | — |
Hemogenyx Pharmaceuticals net income trends
Over the last five fiscal years, Hemogenyx Pharmaceuticals's net income decreased from −£2.1M to −£9.8M, a change of −£7.7M.
About the metric
What net income means
Net income is a company’s bottom-line profit or loss after operating costs, interest, taxes, and other reported income and expenses. It shows how much of a company’s revenue ultimately remained as earnings, or how large its loss was, during a fiscal period.
Calculation and source
reported net income
TickerStat standardizes consolidated net income or profit and loss reported in company official filings for aligned fiscal periods. It is not adjusted earnings, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Hemogenyx Pharmaceuticals source filings ↗Community posts
Hemogenyx loss widens on non-cash options charge despite lower underlying spending
Hemogenyx Pharmaceuticals ($HEMO) reported a first-half pretax loss of £6.56 million, widening from £5.01 million. Reported operating costs increased to £6.48 million, but the company attributed most of the rise to a £5.54 million non-cash ...
